Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in North America, Europe, and the Asia-Pacific. The company's flagship product comprises NaturalVue, a multifocal contact lens for adults with presbyopia and children with myopia. Visioneering Technologies, Inc. was incorporated in 2008 and is headquartered in Alpharetta, Georgia.

Visioneering Technologies, Inc.

Visioneering Technologies, Inc. specializes in the management of myopia and the treatment of presbyopia, offering NaturalVue® Brand 1 Day contact lenses.

Visioneering Technologies Inc. | 1,349 followers on LinkedIn. Makers of NaturalVue® (etafilcon A) Multifocal One Day Contact Lenses | Visioneering Technologies, Inc., headquartered in Alpharetta, Georgia, is an innovative new company that is dedicated to redefining vision. With a portfolio of technologies to address eye care issues such as presbyopia in adults and myopia correction in children, the company uses creative and differentiated design approaches to develop products that will ultimately enhance practitioner and patient experiences. 

VTI holds fourteen issued patents worldwide that address the need for a treatment for presbyopia in the underdeveloped on-eye/in-eye categories, with an additional eight patents pending.

Vice-President, Global Marketing

Layna Mendlinger

Chief Executive Officer & Executive Board Member Visioneering Technologies Inc.

Juan Carlos Aragón

CFO : Private Equity, M&A, ERP, Forecasts, SEC filings, IPOs, Risk & Legal Management, SOX, HR, Comp & Benefits

Brian Lane

Experienced Board Member for both Private & Public Companies; Board Chair, Audit Chair, Comp Committee and Nom/Gov; Cybersecurity Risk Management

Kathy Miller

Visioneering Technologies Inc.

Don’t miss out on the opportunity to attend the Joint Scientific Program/Residents Poster Session on November 8, 1-3 PM in Exhibit Hall H! 🪧 Check out the VTI posters at Academy 2024: • Board 66: “A Unique Multifocal Contact Lens Design Provides Functional Vision for All Presbyopes” - What you’ll learn: See how a contact lens can be a unicorn for presbyopes • Board 74: “Patient Reported Outcomes in a Randomized Controlled Myopia Progression Study (PROTECT) of a Soft Multifocal Contact Lens” - What you’ll learn: - Data confirms happy kids - No noticeable vision compromise - No comfort compromise - Outstanding Year-1 treatment effect The VTI team also welcomes you to Booth #230 to learn how NaturalVue® (etafilcon A) Enhanced Multifocal 1 Day contact lenses accommodate a range of myopic and presbyopic patients. We look forward to connecting with you in Indianapolis! #Academy24 #PROTECT #NaturalVue #Myopia #VTI VTI-RCT-SM11

Breaking News: Data confirms that kids are happy in NaturalVue Multifocal and it works for Myopia Management Curious to explore these exciting breakthroughs further? Join VTI and Chief Medical Officer, Dr. Kuang-mon (Ashley) Tuan for a new-data presentation at Academy 2024. • Session Title: “Just Released: New learnings from the PROTECT Clinical Trial in addition to how NaturalVue Multifocal manages myopia in children” • When: November 8, 8-8:45 AM • Location: JW Marriott in White River A You can expect to hear new insights from the PROTECT MPC Clinical Trial, including: • Pupil size treatment implications, especially relevant for children spending time outdoors • Clinically relevant adjusted treatment effect (equalized for age, sex, pupil size, site, factors that may influence myopic progression) • Children’s subjective responses on quality of life • The lens’ impact on binocular vision #Academy24 #PROTECT #NaturalVue #Myopia #VTI VTI-RCT-SM11

Just In: NaturalVue Multifocal Delivers 89% (or 0.48 D) Reduction in Refractive Error Progression* Want to hear more groundbreaking findings? Join us for another exclusive presentation by VTI’s Chief Medical Officer, Dr. Kuang-mon (Ashley) Tuan . • Session Title: “Just Released: New learnings from the PROTECT Clinical Trial in addition to how NaturalVue Multifocal manages myopia in children” • When: November 8, 8-8:45 AM • Location: JW Marriott in White River A #Academy24 #PROTECT #NaturalVue #Myopia #VTI *Adjusted treatment effect (vs. Control) equalized for age, sex, pupil size, site, factors that may influence myopic progression.

We’re excited to announce our attendance at The American Academy Of Optometry annual meeting in Indianapolis on November 6-9! We invite you to join a presentation by VTI’s Chief Medical Officer, Dr. Kuang-mon (Ashley) Tuan , as she unveils major discoveries in myopia management from our PROTECT RCT. Here are the details: • Session Title: “Accommodative Accuracy of Children Wearing Catenary Curve Multifocal Lenses, 1-Year PROTECT Results” • What You’ll Learn: - High relative plus in NaturalVue has no negative impact to accommodative accuracy - NaturalVue normalizes accommodative accuracy for kids who struggle with focus at near • When: November 7, 8:30-8:45 AM • Location: Indianapolis Convention Center, Room 240-242 #Academy24 #PROTECT #NaturalVue #Myopia #VTI VTI-RCT-SM11

🚨 Myopia is on the rise! 🚨 A recent study published by the British Journal of Ophthalmology revealed that 1 in 3 children worldwide is now nearsighted. This alarming trend highlights the importance of early intervention in managing myopia progression. At VTI, we are committed to addressing the rapid increase in the prevalence of myopia. Our NaturalVue® (etafilcon A) Enhanced Multifocal 1 Day contact lenses enhance vision in the short-term while managing myopia long-term. Read the full CNN article here: https://bit.ly/47JqltI #Myopia #MyopiaManagement #CNN #VTI #NaturalVue MKT-VTI-SM59

Didn’t get a chance to meet up with the VTI team at Vision by Design last week? Discover how you can redefine the patient experience with NaturalVue® (etafilcon A) Enhanced Multifocal 1 Day contact lenses, designed to accommodate a range of myopic and presbyopic patients. Learn more here: https://lnkd.in/eBTJ7ZVD We look forward to supporting your practice! #VTI #NaturalVue #MyopiaManagement

A big thank you to all the dedicated eyecare professionals who connected with us at Vision by Design in Dallas last week! It was a pleasure meeting with such a passionate group, all focused on slowing the progression of myopia and delivering better outcomes for patients. #VTI #NaturalVue #VisionByDesign #vbd2024 #MyopiaManagement #EyeCare #DallasTX #eyeonVBD VTI-RCT-SM10

VTI recently announced the publication of peer-reviewed data from a prospective clinical study with mature presbyopes in Clinical Ophthalmology. The study concluded that NaturalVue® Enhanced Multifocal provided a wide range of functional vision while maintaining clear distance vision for individuals suffering from advanced presbyopia. The article entitled, Evaluation of the Functional Visual Range of a Catenary Curve-Based, Extended Depth-of-Focus Contact Lens for Presbyopia, is available online at Clinical Ophthalmology-Dove Press website. To view the complete peer-reviewed published article, click here: https://ow.ly/iVTA50TAF24 .

Visioneering Technologies Inc.’s CEO, Dr. Juan Carlos Aragon, from the International Myopia Conference in Hainan, China with Dr. Ashley Tuan, presenting VTI's latest data from the PROTECT RCT. The poster, entitled, “Optical Defocus to Influence the Progression of Myopia and Eye Growth Shows Dosage-Dependency in Children”, authored by Dr. Tuan and Dr. Sally Dillehay, shares data from the 1-Year results of the study.

Connect with VTI at Vision by Design, hosted by The American Academy of Orthokeratology and Myopia Control , from October 2-5 in Dallas, Texas! Here’s where to find us: 📍Booth #217 📊 Research Presentation: • Session Title: “Randomized Controlled Trial Corroborates Real-World Studies Data for Myopia Progression Control Using Catenary Power Profile Contact Lenses” • When: October 4, 9:40-10 AM • Where: Reunion GH 🪧 Poster Presentation: • When: October 4, 4:40-5:10 PM • Where: Reunion Foyer We look forward to connecting with you! #VTI #NaturalVue #VisionByDesign #vbd2024 #MyopiaManagement #EyeCare #DallasTX #eyeonVBD

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-16.98M -	-16.73M 1.45%	-18.16M 8.49%	-13.42M 26.08%	-3.11M 76.83%	-5.85M 88.25%
depreciation and amortization	44.73K -	75.96K 69.81%	97.85K 28.82%	193.19K 97.44%	151.88K 21.38%	24K 84.20%
deferred income tax
stock based compensation
change in working capital			-436.01K -	772.77K 277.24%	-987.25K 227.75%	-513.54K 47.98%
accounts receivables			-489.25K -	-158.33K 67.64%	46.63K 129.45%	263.98K 466.11%
inventory			-271.96K -	2.41M 987.14%	-1.14M 147.38%	-647.69K 43.34%
accounts payables			200.02K -	72.63K 63.69%	285.12K 292.57%	-269.75K 194.61%
other working capital			125.19K -	-1.55M 1,341.50%	-175.87K 88.68%	139.92K 179.56%
other non cash items	16.94M -	16.66M 1.64%	289.23K 98.26%	3.00M 937.58%	-6.72M 323.93%	513.54K 107.64%	-5.42M 1,155.83%
net cash provided by operating activities			-18.20M -	-9.45M 48.07%	-10.67M 12.82%	-5.83M 45.34%	-5.42M 7.00%
investments in property plant and equipment	-205K -	-17K 91.71%	-1K 94.12%	-24K 2,300%	-19K 20.83%	-4K 78.95%
acquisitions net
purchases of investments						-9.55M -
sales maturities of investments						7.71M -
other investing activites
net cash used for investing activites	-205K -	-17K 91.71%	-1K 94.12%	-24K 2,300%	-19K 20.83%	-1.84M 9,594.74%
debt repayment			-4.27M -	-1.50M 64.75%		-43K -
common stock issued	23.39M -	6.25M 73.26%	4.33M 30.74%	5.70M 31.65%	16.60M 191.09%		2.48M -
common stock repurchased
dividends paid
other financing activites			7.23M -	2.82M 60.97%
net cash used provided by financing activities	23.39M -	6.25M 73.26%	7.30M 16.64%	7.02M 3.77%	16.60M 136.45%	-43K 100.26%	2.48M 5,856.44%
effect of forex changes on cash			5.55M -	2.95M 46.96%	2.66M 9.68%	-153K 105.75%
net change in cash	10.91M -	-9.31M 185.33%	-5.36M 42.46%	489K 109.13%	8.58M 1,653.99%	-7.87M 191.73%	-4.23M 46.24%
cash at beginning of period	5.67M -	16.58M 192.28%	7.28M 56.13%	1.92M 73.62%	2.41M 25.48%	10.98M 356.19%	4.60M 58.16%
cash at end of period	16.58M -	7.28M 56.13%	1.92M 73.62%	2.41M 25.48%	10.98M 356.19%	3.12M 71.62%	366.38K 88.25%
operating cash flow			-18.20M -	-9.45M 48.07%	-10.67M 12.82%	-5.83M 45.34%	-5.42M 7.00%
capital expenditure	-205K -	-17K 91.71%	-1K 94.12%	-24K 2,300%	-19K 20.83%	-4K 78.95%
free cash flow	-205K -	-17K 91.71%	-18.21M 106,990.72%	-9.48M 47.94%	-10.68M 12.73%	-5.83M 45.40%	-5.42M 7.06%

VTI

COM:VTIVISION

Visioneering Technologies, Inc.

Last Close

0.14

15/11 00:38

Market Cap

7.07M

Beta: -

Volume Today

71

Avg: -

Preview